DAPAGLIFLOZIN ACCEPTED FOR USE WITHIN NHS SCOTLAND
Breaking News Today – 12th April 2021
AstraZeneca today announced that Forxiga (dapagliflozin) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) as an additional option for the treatment of symptomatic chronic heart failure (HF) with reduced ejection fraction (rEF) in adults, as an add-on to already optimised standard care.
Read the two press releases
Scottish Medicines Press Release